Northern Trust Corp Purchases 254,768 Shares of Sotera Health (NASDAQ:SHC)

Northern Trust Corp boosted its holdings in Sotera Health (NASDAQ:SHC - Free Report) by 23.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,334,367 shares of the company's stock after buying an additional 254,768 shares during the period. Northern Trust Corp owned approximately 0.47% of Sotera Health worth $18,254,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the business. Blue Trust Inc. raised its holdings in Sotera Health by 164.3% in the fourth quarter. Blue Trust Inc. now owns 1,834 shares of the company's stock worth $25,000 after purchasing an additional 1,140 shares during the period. Quarry LP acquired a new stake in Sotera Health in the fourth quarter worth $28,000. Tower Research Capital LLC TRC raised its holdings in Sotera Health by 37.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,975 shares of the company's stock worth $82,000 after purchasing an additional 1,640 shares during the period. Sterling Capital Management LLC increased its position in shares of Sotera Health by 58.5% during the fourth quarter. Sterling Capital Management LLC now owns 9,029 shares of the company's stock worth $124,000 after acquiring an additional 3,331 shares in the last quarter. Finally, PNC Financial Services Group Inc. increased its position in shares of Sotera Health by 39.4% during the fourth quarter. PNC Financial Services Group Inc. now owns 9,302 shares of the company's stock worth $127,000 after acquiring an additional 2,627 shares in the last quarter. 91.03% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on SHC shares. The Goldman Sachs Group raised shares of Sotera Health from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $14.00 to $17.00 in a research report on Monday, May 5th. Barclays lowered their price objective on shares of Sotera Health from $16.00 to $12.00 and set an "overweight" rating for the company in a research report on Thursday, April 10th. Finally, Piper Sandler lowered their price objective on shares of Sotera Health from $15.00 to $13.00 and set a "neutral" rating for the company in a research report on Wednesday, April 23rd. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, Sotera Health presently has an average rating of "Moderate Buy" and an average price target of $15.80.

Sotera Health Stock Down 0.5%

Sotera Health stock traded down $0.06 during mid-day trading on Monday, reaching $12.74. The company's stock had a trading volume of 794,533 shares, compared to its average volume of 1,203,083. The company has a market capitalization of $3.62 billion, a price-to-earnings ratio of 50.96 and a beta of 1.88. Sotera Health has a 12 month low of $9.53 and a 12 month high of $17.08. The business's 50 day simple moving average is $11.60 and its 200 day simple moving average is $12.80. The company has a debt-to-equity ratio of 4.91, a quick ratio of 2.61 and a current ratio of 2.88.

Sotera Health (NASDAQ:SHC - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $0.14 earnings per share for the quarter, beating analysts' consensus estimates of $0.12 by $0.02. The business had revenue of $254.52 million during the quarter, compared to the consensus estimate of $245.56 million. Sotera Health had a net margin of 6.31% and a return on equity of 42.27%. The firm's revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter last year, the firm earned $0.13 earnings per share. As a group, research analysts anticipate that Sotera Health will post 0.61 earnings per share for the current year.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.